Skip to main content
. 2022 Jun 22;158(8):893–899. doi: 10.1001/jamadermatol.2022.2149

Figure 4. Evaluation of the Antirituximab Antibody (ARA)–Neutralizing Capacity of the Interaction Between Rituximab (RTX) and Epstein-Barr Virus (EBV)–Immortalized B Cells Expressing CD20.

Figure 4.

Mean fluorescence intensity (MFI) of the interaction between the patients’ serum samples and EBV-immortalized B cells expressing CD20 in the 2 relapsing patients with ARAs compared with nonrelapsing patients with ARAs and patients without ARAs as negative controls. The MFI corresponding to a neutralizing capacity of ARAs was determined using 2 positive controls and is represented by the dotted line.